News & Updates

In the ARAMIS* trial, dual antiplatelet therapy (DAPT) using clopidogrel and aspirin was noninferior to intravenous thrombolysis (IVT) using alteplase in Chinese patients with minor nondisabling ischaemic stroke presenting within 4.5 hours of symptom onset.

The incidence of sexually transmitted infection (STI) over the first 4 years of pre-exposure prophylaxis (PrEP) use remains high and stable, but the incidence of chlamydia and gonorrhea has slightly decreased among daily PrEP users, as shown in a study presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI).

Endovascular treatment (EVT) with intravenous tirofiban prior to thrombectomy appears to improve functional outcome and reduce the risk of any intracranial haemorrhage in patients with large vessel occlusion treated within 4.5 hours after stroke onset compared with alteplase, a study has shown.

Postdiagnostic use of low-dose zinc supplement may help reduce the risk of lethal prostate cancer and all-cause mortality among patients with nonmetastatic prostate cancer, suggests a recent study.

Increased intake of omega-3 fatty acids is associated with lower all-cause mortality in individuals with diabetes, as reported in a study.

Postoperative salvage radiotherapy (SRT) plus 6 months of androgen deprivation therapy (ADT) with abiraterone acetate/prednisone (AAP) and apalutamide (Apa) results in better progression-free (PFS) and metastasis-free survival (MFS) among patients with prostate cancer, findings from FORMULA-509 have shown. However, the primary analysis did not reach the prespecified threshold for statistical significance.

Findings from the RESCUE BT2 study support the potential of tirofiban to improve neurologic outcomes than aspirin in patients with acute ischaemic stroke without visible large or medium vessel occlusion (LVO or MVO) within 24 hours of last known well or of onset of stroke symptom progression. However, its efficacy was countered by the higher rate of symptomatic intracranial haemorrhage (sICH).